TDM-optimized Teicoplanin Dosing Versus Standard of Care - Trial NCT05914467
Access comprehensive clinical trial information for NCT05914467 through Pure Global AI's free database. This Phase 4 trial is sponsored by Radboud University Medical Center and is currently Not yet recruiting. The study focuses on Bacterial Infections. Target enrollment is 74 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Radboud University Medical Center
Timeline & Enrollment
Phase 4
Jul 01, 2023
Dec 30, 2024
Primary Outcome
Fraction of participants that reaches therapeutic exposure after 5 days of treatment
Summary
Value of TDM for teicoplanin is not well defined. In this single-center low-interventional
 randomized trial the investigators aim to investigate the superiority of teicoplanin
 TDM-optimized using Model-Informed-Precision-Dosing (MIPD) of unbound concentrations versus
 the standard of care (dosing based on antibiotic guidelines) in target attainment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05914467
Non-Device Trial